Chuan Gu

Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study

Yuankai Shi, Gongyan Chen, Xiang Wang et al. · The Lancet Respiratory Medicine · 2022 · 211 citations

Versus Gefitinib, Medicine, Pathology +8

Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study

Yuankai Shi, Xingsheng Hu, Shucai Zhang et al. · The Lancet Respiratory Medicine · 2021 · 115 citations

Genetic Analysis, Egfr T790m, Phase 2B +12

Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study

Yuankai Shi, Gongyan Chen, Xiang Wang et al. · Journal of Thoracic Oncology · 2022 · 71 citations

Neuro-oncology, Versus Gefitinib, Furlong Study +6

CMTM6 significantly relates to PD-L1 and predicts the prognosis of gastric cancer patients

Xin Li, Ling Chen, Chuan Gu et al. · PeerJ · 2020 · 42 citations · Full text

Regulation of motilin release: studies with ex vivo perfused canine jejunum

P. Poitras, L. Trudel, Paul J. Miller et al. · American Journal of Physiology-Gastrointestinal and Liver Physiology · 1997 · 15 citations

Animal Physiology, Isolated Intestine, Regulatory Process +13